ATX-007CP4DV12

In Re: Harrington, et al. Appl. No.: 09/484,331

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the applications:

Listing of Claims:

Please cancel Claims 1-68.

Claim 69 (previously presented): A method for drug discovery comprising:

- (a) integrating a vector, comprising a promoter, into the genome of one or more eukaryotic cells, by non-homologous recombination, wherein said promoter activates expression of an endogenous gene in said one or more cells;
- (b) culturing said one or more cells under conditions favoring expression of said activated gene, thereby producing a gene product of said activated gene;
- (c) screening said one or more cells for a cell in which a desired gene is activated or for a cell in which a desired phenotype is induced by said activated gene;
- (d) treating said cell, in which said desired gene is activated or in which said desired phenotype is induced, with one or more test compounds to be screened for drug activity; and
- (e) determining the ability of said one or more test compounds to interact with a product of said desired activated gene or to affect said desired phenotype.

In Re: Harrington, *et al.* Appl. No.: 09/484,331

Claim 70 (currently amended) The method of claim 62 or claim 69 wherein the gene product is protein, the protein is purified from the cell and the test compound is exposed to the purified protein.